GT Biopharma

Youtube Subscribe

Open: 0.24 Close: 0.24 Change: 0.0

You're losing the opportunity of using an AI to get informed about GT Biopharma Stock.

This document will help you to evaluate GT Biopharma without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about GT Biopharma are: GT, Biopharma, leukemia, Stockholders, stockholder, vote, solid, …

Concept Map

Semantic Network

Stock Summary

GT Biopharma, Inc. focuses on the development and commercialization of immuno-oncology products. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate. GT.

Today's Summary

GT Biopharma is generating novel immuno-oncology biopharmaceutical drugs targeting cancers such as acute myeloid leukemia, myeloids dysplastic syndrome, and multiple solid tumors. Nasdaq requires that a listed company maintain a minimum bid price of $1.00 per share.

Today's News

Leading Proxy Advisory Firms, ISS and Glass Lewis, Recommend GT Biopharma Stockholders Vote “FOR” All Proposed Items at the Upcoming Special Meeting of Stockholders. The deadline for stockholders to vote (or change their vote) is 11:59 p.m. GT Biopharma is generating novel immuno-oncology biopharmaceutical drugs targeting cancers such as acute myeloid leukemia, myeloids dysplastic syndrome, and multiple solid tumors. GTB-3650 for treatment of CD33+ leukemia. Nasdaq requires that a listed company maintain a minimum bid price of $1.00 per share. GT Biopharma is requesting approval from its stockholders to have the option to implement a Reverse Split. GT Biopharma submits IND to FDA for CD33+ leukemia therapy. GTB-3650 has shown high potency in preclinical models, as well as enhanced binding affinity. GT Biopharma has demonstrated record-breaking revenue, particularly driven by the sales of its main products. As of 2023, GTBiopharma is poised for continued success in the biotechnology industry. With a solid financial performance, GTBP is well-positioned.

Stock Profile

"GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California."

Keywords

Are looking for the most relevant information about GT Biopharma? Investor spend a lot of time searching for information to make investment decisions in GT Biopharma. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about GT Biopharma are: GT, Biopharma, leukemia, Stockholders, stockholder, vote, solid, and the most common words in the summary are: excipient, phase, gt, biopharma, news, sodium, glycol, . One of the sentences in the summary was: GT Biopharma is generating novel immuno-oncology biopharmaceutical drugs targeting cancers such as acute myeloid leukemia, myeloids dysplastic syndrome, and multiple solid tumors. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #excipient #phase #gt #biopharma #news #sodium #glycol.

Read more →

Youtube Subscribe

---